, Volume 7, Issue 4, pp 354–365 | Cite as

Microglial activation and chronic neurodegeneration

  • Melinda E. Lull
  • Michelle L. BlockEmail author
Review Article


Microglia, the resident innate immune cells in the brain, have long been implicated in the pathology of neurode-generative diseases. Accumulating evidence points to activated microglia as a chronic source of multiple neurotoxic factors, including tumor necrosis factor-α, nitric oxide, interleukin-1β, and reactive oxygen species (ROS), driving progressive neuron damage. Microglia can become chronically activated by either a single stimulus (e.g., lipopolysaccharide or neuron damage) or multiple stimuli exposures to result in cumulative neuronal loss with time. Although the mechanisms driving these phenomena are just beginning to be understood, reactive microgliosis (the microglial response to neuron damage) and ROS have been implicated as key mechanisms of chronic and neurotoxic microglial activation, particularly in the case of Parkinson’s disease. We review the mechanisms of neurotoxicity associated with chronic microglial activation and discuss the role of neuronal death and microglial ROS driving the chronic and toxic microglial phenotype.

Key Words

Microglia inflammation-mediated neurodegeneration oxidative stress chronic neurotoxicity reactive microgliosis 


  1. 1.
    Block ML, Hong JS. Chronic microglial activation and progressive dopaminergic neurotoxicity. Biochem Soc Trans 2007;35: 1127–32.PubMedGoogle Scholar
  2. 2.
    del Rio-Hortega P. Cytology and cellular pathology of the nervous system. New York: Penfeild Wed, 1932.Google Scholar
  3. 3.
    Morris L, Graham CF, Gordon S. Macrophages in haemopoietic and other tissues of the developing mouse detected by the monoclonal antibody F4/80. Development 1991;112: 517–26.PubMedGoogle Scholar
  4. 4.
    Alliot F, Godin I, Pessac B. Microglia derive from progenitors, originating from the yolk sac, and which proliferate in the brain. Brain Res Dev Brain Res 1999;117: 145–52.PubMedGoogle Scholar
  5. 5.
    Rezaie P, Trillo-Pazos G, Greenwood J, Everall IP, Male DK. Motility and ramification of human fetal microglia in culture: an investigation using time-lapse video microscopy and image analysis. Exp Cell Res 2002;274: 68–82.PubMedGoogle Scholar
  6. 6.
    Ling EA, Wong WC. The origin and nature of ramified and amoeboid microglia: a historical review and current concepts. Glia 1993;7: 9–18.PubMedGoogle Scholar
  7. 7.
    Dalmau I, Vela JM, Gonzalez B, Finsen B, Castellano B. Dynamics of microglia in the developing rat brain. J Comp Neurol 2003;458: 144–57.PubMedGoogle Scholar
  8. 8.
    Soulet D, Rivest S. Bone-marrow-derived microglia: myth or reality? Curr Opin Pharmacol 2008;8: 508–18.PubMedGoogle Scholar
  9. 9.
    Mildner A, Schmidt H, Nitsche M, et al. Microglia in the adult brain arise from Ly-6ChiCCR2+ monocytes only under defined host conditions. Nat Neurosci 2007;10: 1544–53.PubMedGoogle Scholar
  10. 10.
    Geissmann F, Jung S, Littman DR. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 2003;19: 71–82.PubMedGoogle Scholar
  11. 11.
    Flugel A, Bradl M, Kreutzberg GW, Graeber MB. Transformation of donor-derived bone marrow precursors into host microglia during autoimmune CNS inflammation and during the retrograde response to axotomy. J Neurosci Res 2001;66: 74–82.PubMedGoogle Scholar
  12. 12.
    Hickey WF, Kimura H. Perivascular microglial cells of the CNS are bone marrow-derived and present antigen in vivo. Science 1988;239: 290–2.PubMedGoogle Scholar
  13. 13.
    Streit WJ, Graeber MB, Kreutzberg GW. Expression of Ia antigen on perivascular and microglial cells after sublethal and lethal motor neuron injury. Exp Neurol 1989;105: 115–26.PubMedGoogle Scholar
  14. 14.
    Shechter R, London A, Varol C, et al. Infiltrating blood-derived macrophages are vital cells playing an anti-inflammatory role in recovery from spinal cord injury in mice. PLoS Med 2009;6: e1000113.PubMedGoogle Scholar
  15. 15.
    Lawson LJ, Perry VH, Gordon S. Turnover of resident microglia in the normal adult mouse brain. Neuroscience 1992;48: 405–15.PubMedGoogle Scholar
  16. 16.
    Ajami B, Bennett JL, Krieger C, Tetzlaff W, Rossi FM. Local self-renewal can sustain CNS microglia maintenance and function throughout adult life. Nat Neurosci 2007;10: 1538–43.PubMedGoogle Scholar
  17. 17.
    Alliot F, Lecain E, Grima B, Pessac B. Microglial progenitors with a high proliferative potential in the embryonic and adult mouse brain. Proc Natl Acad Sci U S A 1991;88: 1541–5.PubMedGoogle Scholar
  18. 18.
    Aloisi F. Immune function of microglia. Glia 2001;36: 165–79.PubMedGoogle Scholar
  19. 19.
    Adams RA, Bauer J, Flick MJ, et al. The fibrin-derived gamma377-395 peptide inhibits microglia activation and suppresses relapsing paralysis in central nervous system autoimmune disease. J Exp Med 2007;204: 571–82.PubMedGoogle Scholar
  20. 20.
    Hoek RM, Ruuls SR, Murphy CA, et al. Down-regulation of the macrophage lineage through interaction with OX2 (CD200). Science 2000;290: 1768–71.PubMedGoogle Scholar
  21. 21.
    Harrison JK, Jiang Y, Chen S, et al. Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. Proc Natl Acad Sci U S A 1998;95: 10896–901.PubMedGoogle Scholar
  22. 22.
    Lawson LJ, Perry VH, Dri P, Gordon S. Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience 1990;39: 151–70.PubMedGoogle Scholar
  23. 23.
    Davalos D, Grutzendler J, Yang G, et al. ATP mediates rapid microglial response to local brain injury in vivo. Nat Neurosci 2005;8: 752–8.PubMedGoogle Scholar
  24. 24.
    Nimmerjahn A, Kirchhoff F, Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 2005;308: 1314–1318.PubMedGoogle Scholar
  25. 25.
    Kreutzberg GW. Microglia: a sensor for pathological events in the CNS. Trends Neurosci 1996;19: 312–8.PubMedGoogle Scholar
  26. 26.
    Graeber MB, Streit WJ, Kreutzberg GW. Axotomy of the rat facial nerve leads to increased CR3 complement receptor expression by activated microglial cells. J Neurosci Res 1988;21: 18–24.PubMedGoogle Scholar
  27. 27.
    Colton CA, Gilbert DL. Production of Superoxide anions by a CNS macrophage, the microglia. FEBS Lett 1987;223: 284–8.PubMedGoogle Scholar
  28. 28.
    Hurley SD, Walter SA, Semple-Rowland SL, Streit WJ. Cytokine transcripts expressed by microglia in vitro are not expressed by ameboid microglia of the developing rat central nervous system. Glia 1999;25: 304–9.PubMedGoogle Scholar
  29. 29.
    Si Q, Kim MO, Zhao ML, Landau NR, Goldstein H, Lee S. Vpr- and Nef-dependent induction of RANTES/CCL5 in microglial cells. Virology 2002;301: 342–53.PubMedGoogle Scholar
  30. 30.
    Liu B, Hong JS. Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J Pharmacol Exp Ther 2003;304: 1–7.PubMedGoogle Scholar
  31. 31.
    Streit WJ, Graeber MB, Kreutzberg GW. Functional plasticity of microglia: a review. Glia 1988;1: 301–7.PubMedGoogle Scholar
  32. 32.
    Streit WJ, Walter SA, Pennell NA. Reactive microgliosis. Prog Neurobiol 1999;57: 563–81.PubMedGoogle Scholar
  33. 33.
    Lynch MA. The multifaceted profile of activated microglia. Mol Neurobiol 2009;40: 139–56.PubMedGoogle Scholar
  34. 34.
    Elkabes S, DiCicco-Bloom EM, Black IB. Brain microglia/macrophages express neurotrophins that selectively regulate microglial proliferation and function. J Neurosci 1996;16: 2508–21.PubMedGoogle Scholar
  35. 35.
    Blinzinger K, Kreutzberg G. Displacement of synaptic terminals from regenerating motoneurons by microglial cells. Z Zeilforsch Mikrosk Anat 1968;85: 145–57.Google Scholar
  36. 36.
    Graeber MB, Streit WJ. Microglia: biology and pathology. Acta Neuropathol;119:89–105.Google Scholar
  37. 37.
    Zhong Y, Zhou LJ, Ren WJ, et al. The direction of synaptic plasticity mediated by C-fibers in spinal dorsal horn is decided by Src-family kinases in microglia: the role of tumor necrosis factor-alpha. Brain Behav Immun 2010;24: 874–80.PubMedGoogle Scholar
  38. 38.
    Batchelor PE, Liberatore GT, Wong JY, et al. Activated macrophages and microglia induce dopaminergic sprouting in the injured striatum and express brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor. J Neurosci 1999;19: 1708–1716.PubMedGoogle Scholar
  39. 39.
    Batchelor PE, Porritt MJ, Martinello P, et al. Macrophages and microglia produce local trophic gradients that stimulate axonal sprouting toward but not beyond the wound edge. Mol Cell Neurosci 2002;21: 436–53.PubMedGoogle Scholar
  40. 40.
    Yamada J, Hayashi Y, Jinno S, et al. Reduced synaptic activity precedes synaptic stripping in vagal motoneurons after axotomy. Glia 2008;56: 1448–62.PubMedGoogle Scholar
  41. 41.
    Trapp BD, Wujek JR, Criste GA, et al. Evidence for synaptic stripping by cortical microglia. Glia 2007;55: 360–8.PubMedGoogle Scholar
  42. 42.
    Siskova Z, Page A, O’Connor V, Perry VH. Degenerating synaptic boutons in prion disease: microglia activation without synaptic stripping. Am J Pathol 2009;175: 1610–21.PubMedGoogle Scholar
  43. 43.
    Liao H, Bu WY, Wang TH, Ahmed S, Xiao ZC. Tenascin-R plays a role in neuroprotection via its distinct domains that coordinate to modulate the microglia function. J Biol Chem 2005;280: 8316–8323.PubMedGoogle Scholar
  44. 44.
    Morgan SC, Taylor DL, Pocock JM. Microglia release activators of neuronal proliferation mediated by activation of mitogen-activated protein kinase, phosphatidylinositol-3-kinase/Akt and delta-Notch signalling cascades. J Neurochem 2004;90: 89–101.PubMedGoogle Scholar
  45. 45.
    Ransohoff RM, Perry VH. Microglial physiology: unique stimuli, specialized responses. Annu Rev Immunol 2009;27: 119–45.PubMedGoogle Scholar
  46. 46.
    Block ML, Hong JS. Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog Neurobiol 2005;76: 77–98.PubMedGoogle Scholar
  47. 47.
    Graeber MB, Streit WJ, Kreutzberg GW. The microglial cytoskeleton: vimentin is localized within activated cells in situ. J Neurocytol 1988;17: 573–80.PubMedGoogle Scholar
  48. 48.
    Oehmichen W, Gencic M. Experimental studies on kinetics and functions of monuclear phagozytes of the central nervous system. Acta Neuropathol Suppl (Berl) 1975;(suppl 6):285–90.Google Scholar
  49. 49.
    Pei Z, Pang H, Qian L, et al. MAC1 mediates LPS-induced production of Superoxide by microglia: the role of pattern recognition receptors in dopaminergic neurotoxicity. Glia 2007;55: 1362–73.PubMedGoogle Scholar
  50. 50.
    Qin L, Li G, Qian X, et al. Interactive role of the toll-like receptor 4 and reactive oxygen species in LPS-induced microglia activation. Glia 2005;52: 78–84.PubMedGoogle Scholar
  51. 51.
    Qin L, Liu Y, Qian X, Hong JS, Block ML. Microglial NADPH oxidase mediates leucine enkephalin dopaminergic neuroprotection. Ann N Y Acad Sci 2005;1053: 107–20.PubMedGoogle Scholar
  52. 52.
    Wu X, Block ML, Zhang W, et al. The role of microglia in paraquat-induced dopaminergic neurotoxicity. Antioxid Redox Signal 2005;7: 654–61.PubMedGoogle Scholar
  53. 53.
    Mao H, Fang X, Floyd KM, Polcz JE, Zhang P, Liu B. Induction of microglial reactive oxygen species production by the organochlorinated pesticide dieldrin. Brain Res 2007;1186: 267–74.PubMedGoogle Scholar
  54. 54.
    Mao H, Liu B. Synergistic microglial reactive oxygen species generation induced by pesticides lindane and dieldrin. Neuroreport 2008;19: 1317–20.PubMedGoogle Scholar
  55. 55.
    Gao HM, Hong JS, Zhang W, Liu B. Synergistic dopaminergic neurotoxicity of the pesticide rotenone and inflammogen lipopolysaccharide: relevance to the etiology of Parkinson’s disease. J Neurosci 2003;23: 1228–36.PubMedGoogle Scholar
  56. 56.
    Bamberger ME, Landreth GE. Microglial interaction with beta-amyloid: implications for the pathogenesis of Alzheimer’s disease. Microsc Res Tech 2001;54: 59–70.PubMedGoogle Scholar
  57. 57.
    Zhang W, Wang T, Pei Z, et al. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson’s disease. Faseb J 2005;19: 533–42.PubMedGoogle Scholar
  58. 58.
    Turchan-Cholewo J, Dimayuga FO, Gupta S, et al. Morphine and HIV-Tat increase microglial-free radical production and oxidative stress: possible role in cytokine regulation. J Neurochem 2009;108: 202–15.PubMedGoogle Scholar
  59. 59.
    Block ML, Calderon-Garciduenas L. Air pollution: mechanisms of neuroinflammation and CNS disease. Trends Neurosci 2009: 32: 506–16.PubMedGoogle Scholar
  60. 60.
    Moss DW, Bates TE. Activation of murine microglial cell lines by lipopolysaccharide and interferon-gamma causes NO-mediated decreases in mitochondrial and cellular function. Eur J Neurosci 2001;13: 529–38.PubMedGoogle Scholar
  61. 61.
    Liu B, Gao HM, Wang JY, Jeohn GH, Cooper CL, Hong JS. Role of nitric oxide in inflammation-mediated neurodegeneration. Ann N Y Acad Sci 2002;962: 318–31.PubMedGoogle Scholar
  62. 62.
    Sawada M, Kondo N, Suzumura A, Marunouchi T. Production of tumor necrosis factor-alpha by microglia and astrocytes in culture. Brain Res 1989;491: 394–7.PubMedGoogle Scholar
  63. 63.
    Lee SC, Liu W, Dickson DW, Brosnan CF, Berman JW. Cytokine production by human fetal microglia and astrocytes. Differential induction by lipopolysaccharide and IL-1 beta. J Immunol 1993;150: 2659–67.PubMedGoogle Scholar
  64. 64.
    Wang T, Pei Z, Zhang W, et al. MPP+-induced COX-2 activation and subsequent dopaminergic neurodegeneration. Faseb J 2005;19: 1134–1136.PubMedGoogle Scholar
  65. 65.
    Liu B, Gao HM, Hong JS. Parkinson’s disease and exposure to infectious agents and pesticides and the occurrence of brain injuries: role of neuroinflammation. Environ Health Perspect 2003;111: 1065–1073.PubMedGoogle Scholar
  66. 66.
    Olson EE, McKeon RJ. Characterization of cellular and neurological damage following unilateral hypoxia/ischemia. J Neurol Sci 2004;227: 7–19.PubMedGoogle Scholar
  67. 67.
    Morioka T, Kalehua AN, Streit WJ. Characterization of microglial reaction after middle cerebral artery occlusion in rat brain. J Comp Neurol 1993;327: 123–32.PubMedGoogle Scholar
  68. 68.
    Tsuda M, Mizokoshi A, Shigemoto-Mogami Y, Koizumi S, Inoue K. Activation of p38 mitogen-activated protein kinase in spinal hyperactive microglia contributes to pain hypersensitivity following peripheral nerve injury. Glia 2004;45: 89–95.PubMedGoogle Scholar
  69. 69.
    McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains. Neurology 1988;38: 1285–91.PubMedGoogle Scholar
  70. 70.
    Ziehn MO, Avedisian AA, Tiwari-Woodruff S, Voskuhl RR. Hippocampal CA1 atrophy and synaptic loss during experimental autoimmune encephalomyelitis, EAE. Lab Invest 2010;90: 774–786.PubMedGoogle Scholar
  71. 71.
    Banati RB, Gehrmann J, Kellner M, Holsboer F. Antibodies against microglia/brain macrophages in the cerebrospinal fluid of a patient with acute amyotrophic lateral sclerosis and presenile dementia. Clin Neuropathol 1995;14: 197–200.PubMedGoogle Scholar
  72. 72.
    Hall ED, Oostveen JA, Gurney ME. Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. Glia 1998;23: 249–56.PubMedGoogle Scholar
  73. 73.
    Bell JE, Arango JC, Robertson R, Brettle RP, Leen C, Simmonds P. HIV and drug misuse in the Edinburgh cohort. J Acquir Immune Defic Syndr 2002;31(suppl 2): S35–42.PubMedGoogle Scholar
  74. 74.
    Miller KR, Streit WJ. The effects of aging, injury and disease on microglial function: a case for cellular senescence. Neuron Glia Biol 2007;3: 245–53.PubMedGoogle Scholar
  75. 75.
    Finch GL, Hobbs CH, Blair LF, et al. Effects of subchronic inhalation exposure of rats to emissions from a diesel engine burning soybean oil-derived biodiesel fuel. Inhal Toxicol 2002;14: 1017–48.PubMedGoogle Scholar
  76. 76.
    Yankner BA. Amyloid and Alzheimer’s disease—cause or effect? Neurobiol Aging 1989;10: 470–8.PubMedGoogle Scholar
  77. 77.
    Rogers J, Luber-Narod J, Styren SD, Civin WH. Expression of immune system-associated antigens by cells of the human central nervous system: relationship to the pathology of Alzheimer’s disease. Neurobiol Aging 1988;9: 339–49.PubMedGoogle Scholar
  78. 78.
    McGeer PL, Itagaki S, Tago H, McGeer EG. Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. Neurosci Lett 1987;79: 195–200.PubMedGoogle Scholar
  79. 79.
    Yankner BA, Duffy LK, Kirschner DA. Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science 1990;250: 279–82.PubMedGoogle Scholar
  80. 80.
    Sasaki A, Yamaguchi H, Ogawa A, Sugihara S, Nakazato Y. Microglial activation in early stages of amyloid beta protein deposition. Acta Neuropathol (Berl) 1997;94: 316–22.Google Scholar
  81. 81.
    Meda L, Cassatella MA, Szendrei GI, et al. Activation of microglial cells by beta-amyloid protein and interferon-gamma. Nature 1995;374: 647–50.PubMedGoogle Scholar
  82. 82.
    Banati RB, Newcombe J, Gunn RN, et al. The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain 2000;123(Pt 11): 2321–37.PubMedGoogle Scholar
  83. 83.
    Peterson JW, Bo L, Mork S, Chang A, Trapp BD. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol 2001;50: 389–400.PubMedGoogle Scholar
  84. 84.
    Takeuchi H, Wang J, Kawanokuchi J, Mitsuma N, Mizuno T, Suzumura A. Interferon-gamma induces microglial-activation-induced cell death: a hypothetical mechanism of relapse and remission in multiple sclerosis. Neurobiol Dis 2006;22: 33–9.PubMedGoogle Scholar
  85. 85.
    Murphy AC, Lalor SJ, Lynch MA, Mills KH. Infiltration of Th1 and Th17 cells and activation of microglia in the CNS during the course of experimental autoimmune encephalomyelitis. Brain Behav Immun 2010;24: 641–651.PubMedGoogle Scholar
  86. 86.
    Liu Y, Hao W, Letiembre M, et al. Suppression of microglial inflammatory activity by myelin phagocytosis: role of p47-PHOX-mediated generation of reactive oxygen species. J Neurosci 2006;26: 12904–13.PubMedGoogle Scholar
  87. 87.
    Mack CL, Vanderlugt-Castaneda CL, Neville KL, Miller SD. Microglia are activated to become competent antigen presenting and effector cells in the inflammatory environment of the Theiler’s virus model of multiple sclerosis. J Neuroimmunol 2003;144: 68–79.PubMedGoogle Scholar
  88. 88.
    Jordan CA, Watkins BA, Kufta C, Dubois-Dalcq M. Infection of brain microglial cells by human immunodeficiency virus type 1 is CD4 dependent. J Virol 1991;65: 736–42.PubMedGoogle Scholar
  89. 89.
    Speth C, Dierich MP, Sopper S. HIV-infection of the cental nervous system: the tightrope walk of innate immunity. Mol Immunol 2005;42: 213–28.PubMedGoogle Scholar
  90. 90.
    Brabers NA, Nottet HS. Role of the pro-inflammatory cytokines TNF-alpha and IL-1beta in HIV-associated dementia. Eur J Clin Invest 2006;36: 447–58.PubMedGoogle Scholar
  91. 91.
    Turchan-Cholewo J, Dimayuga VM, Gupta S, Gorospe RM, Keller JN, Bruce-Keller AJ. NADPH oxidase drives cytokine and neurotoxin release from microglia and macrophages in response to HIV-Tat. Antioxid Redox Signal 2009;11: 193–204.PubMedGoogle Scholar
  92. 92.
    Polazzi E, Contestabile A. Neuron-conditioned media differentially affect the survival of activated or unstimulated microglia: evidence for neuronal control on apoptotic elimination of activated microglia. J Neuropathol Exp Neurol 2003;62: 351–62.PubMedGoogle Scholar
  93. 93.
    McGeer EG, Klegeris A, McGeer PL. Inflammation, the complement system and the diseases of aging. Neurobiol Aging 2005;26(suppl 1): 94–7.PubMedGoogle Scholar
  94. 94.
    Block ML, Zecca L, Hong JS. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 2007;8: 57–69.PubMedGoogle Scholar
  95. 95.
    Long-Smith CM, Sullivan AM, Nolan YM. The influence of microglia on the pathogenesis of Parkinson’s disease. Prog Neurobiol 2009;89: 277–87.PubMedGoogle Scholar
  96. 96.
    Boje KM, Arora PK. Microglial-produced nitric oxide and reactive nitrogen oxides mediate neuronal cell death. Brain Res 1992: 587: 250–6.PubMedGoogle Scholar
  97. 97.
    Chao CC, Hu S, Molitor TW, Shaskan EG, Peterson PK. Activated microglia mediate neuronal cell injury via a nitric oxide mechanism. J Immunol 1992;149: 2736–41.PubMedGoogle Scholar
  98. 98.
    Frank-Cannon TC, Alto LT, McAlpine FE, Tansey MG. Does neuroinflammation fan the flame in neurodegenerative diseases? Mol Neurodegener 2009;4: 47.PubMedGoogle Scholar
  99. 99.
    McCoy MK, Tansey MG. TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J Neuroinflammation 2008;5: 45.PubMedGoogle Scholar
  100. 100.
    Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu T. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from Parkinsonian patients. Neurosci Lett 1994;165: 208–10.PubMedGoogle Scholar
  101. 101.
    Blum-Degen D, Muller T, Kuhn W, Gerlach M, Przuntek H, Riederer P. Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer’s and de novo Parkinson’s disease patients. Neurosci Lett 1995;202: 17–20.PubMedGoogle Scholar
  102. 102.
    Muller T, Blum-Degen D, Przuntek H, Kuhn W. Interleukin-6 levels in cerebrospinal fluid inversely correlate to severity of Parkinson’s disease. Acta Neurol Scand 1998;98: 142–4.PubMedGoogle Scholar
  103. 103.
    Nagatsu T, Mogi M, Ichinose H, Togari A. Changes in cytokines and neurotrophins in Parkinson’s disease. J Neural Transm Suppl 2000: 60: 277–90.PubMedGoogle Scholar
  104. 104.
    Nagatsu T, Mogi M, Ichinose H, Togari A. Cytokines in Parkinson’s disease. J Neural Transm Suppl 2000: 58: 143–51.PubMedGoogle Scholar
  105. 105.
    Knott C, Stern G, Wilkin GP. Inflammatory regulators in Parkinson’s disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2. Mol Cell Neurosci 2000;16: 724–39.PubMedGoogle Scholar
  106. 106.
    Sriram K, O’Callaghan JP. Divergent roles for tumor necrosis factor-alpha in the brain. J Neuroimmune Pharmacol 2007;2: 140–53.PubMedGoogle Scholar
  107. 107.
    Sriram K, Matheson JM, Benkovic SA, Miller DB, Luster ML O’Callaghan JP. Deficiency of TNF receptors suppresses microglial activation and alters the susceptibility of brain regions to MPTP-induced neurotoxicity: role of TNF-alpha. Faseb J 2006;20: 670–82.PubMedGoogle Scholar
  108. 108.
    Sriram K, Matheson JM, Benkovic SA, Miller DB, Luster MI, O’Callaghan JP. Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson’s disease. Faseb J 2002;16: 1474–6.PubMedGoogle Scholar
  109. 109.
    De Lella Ezcurra AL, Chertoff M, Ferrari C, Graciarena M, Pitossi F. Chronic expression of low levels of tumor necrosis factor-alpha in the substantia nigra elicits progressive neurode-generation, delayed motor symptoms and microglia/macrophage activation. Neurobiol Dis;37:630–40.Google Scholar
  110. 110.
    Lee JK, Tran T, Tansey MG. Neuroinflammation in Parkinson’s disease. J Neuroimmune Pharmacol 2009;4: 419–29.PubMedGoogle Scholar
  111. 111.
    Nimmo AJ, Vink R. Recent patents in CNS drug discovery: the management of inflammation in the central nervous system. Recent Pat CNS Drug Discov 2009;4: 86–95.PubMedGoogle Scholar
  112. 112.
    Hirsch EC, Hunot S. Neuroinflammation in Parkinson’s disease: a target for neuroprotection? Lancet Neurol 2009;8: 382–97.PubMedGoogle Scholar
  113. 113.
    Tansey MG, Goldberg MS. Neuroinflammation in Parkinson’s disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis;37:510–8.Google Scholar
  114. 114.
    Lee JK, McCoy MK, Harms AS, Ruhn KA, Gold SJ, Tansey MG. Regulator of G-protein signaling 10 promotes dopaminergic neuron survival via regulation of the microglial inflammatory response. J Neurosci 2008;28: 8517–28.PubMedGoogle Scholar
  115. 115.
    Langsten JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983;219: 979–80.Google Scholar
  116. 116.
    Jackson-Lewis V, Przedborski S. Protocol for the MPTP mouse model of Parkinson’s disease. Nat Protoc 2007;2: 141–51.PubMedGoogle Scholar
  117. 117.
    Czlonkowska A, Kohutnicka M, Kurkowska-Jastrzebska I, Czlonkowski A. Microglial reaction in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) induced Parkinson’s disease mice model. Neurodegeneration 1996;5: 137–43.PubMedGoogle Scholar
  118. 118.
    Kurkowska-Jastrzebska I, Wronska A, Kohutnicka M, Czlonkowski A, Czlonkowska A. The inflammatory reaction following 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine intoxication in mouse. Exp Neurol 1999;156: 50–61.PubMedGoogle Scholar
  119. 119.
    Hurley SD, O’Banion MK, Song DD, Arana FS, Olschowka JA, Haber SN. Microglial response is poorly correlated with neurodegeneration following chronic, low-dose MPTP administration in monkeys. Exp Neurol 2003;184: 659–68.PubMedGoogle Scholar
  120. 120.
    Barcia C, Sanchez Bahillo A, Fernandez-Villalba E, et al. Evidence of active microglia in substantia nigra pars compacta of Parkinsonian monkeys 1 year after MPTP exposure. Glia 2004;46: 402–9.PubMedGoogle Scholar
  121. 121.
    Cicchetti F, Brownell AL, Williams K, Chen YI, Livni E, Isacson O. Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging. Eur J Neurosci 2002;15: 991–8.PubMedGoogle Scholar
  122. 122.
    Langsten JW, Forno LS, Tetrud J, Reeves AG, Kaplan JA, Karluk D. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol 1999;46: 598–605.Google Scholar
  123. 123.
    Hunot S, Brugg B, Ricard D, et al. Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with Parkinson disease. Proc Natl Acad Sci U S A 1997;94: 7531–6.PubMedGoogle Scholar
  124. 124.
    Ouchi Y, Yagi S, Yokokura M, Sakamoto M. Neuroinflammation in the living brain of Parkinson’s disease. Parkinsonism Relat Disord 2009;15(suppl 3): S200–4.PubMedGoogle Scholar
  125. 125.
    Ouchi Y, Yoshikawa E, Sekine Y, et al. Microglial activation and dopamine terminal loss in early Parkinson’s disease. Ann Neurol 2005;57: 168–75.PubMedGoogle Scholar
  126. 126.
    Gao HM, Liu B, Hong JS. Critical role for microglial NADPH oxidase in rotenone-induced degeneration of dopaminergic neurons. J Neurosci 2003;23: 6181–7.PubMedGoogle Scholar
  127. 127.
    Block ML, Wu X, Pei Z, et al. Nanometer size diesel exhaust particles are selectively toxic to dopaminergic neurons: the role of microglia, phagocytosis, and NADPH oxidase. Faseb J 2004;18: 1618–20.PubMedGoogle Scholar
  128. 128.
    Qin L, Liu Y, Cooper C, Liu B, Wilson B, Hong JS. Microglia enhance beta-amyloid peptide-induced toxicity in cortical and mesencephalic neurons by producing reactive oxygen species. J Neurochem 2002;83: 973–83.PubMedGoogle Scholar
  129. 129.
    Gao HM, Jiang J, Wilson B, Zhang W, Hong JS, Liu B. Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson’s disease. J Neurochem 2002;81: 1285–97.PubMedGoogle Scholar
  130. 130.
    Qin L, Liu Y, Wang T, et al. NADPH oxidase mediates lipopolysaccharide-induced neurotoxicity and proinflammatory gene expression in activated microglia. J Biol Chem 2004;279: 1415–21.PubMedGoogle Scholar
  131. 131.
    Paulsen CE, Carroll KS. Orchestrating redox signaling networks through regulatory cysteine switches. ACS Chem Biol;5:47-62.Google Scholar
  132. 132.
    Circu ML, Aw TY. Reactive oxygen species, cellular redox systems, and apoptosis. Free Radic Biol Med;48:749–62.Google Scholar
  133. 133.
    Babior BM. Phagocytes and oxidative stress. Am J Med 2000;109: 33–44.PubMedGoogle Scholar
  134. 134.
    Nam HJ, Park YY, Yoon G, Cho H, Lee JH. Co-treatment with hepatocyte growth factor and TGF-b1 enhances migration of HaCaT cells through NADPH oxidase-dependent ROS generation. Exp Mol Med 2010;30: 270–279.Google Scholar
  135. 135.
    Sun HN, Kim SU, Lee MS, et al. Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase-dependent activation of phosphoinositide 3-kinase and p38 mitogen-activated protein kinase signal pathways is required for lipopolysaccharide-induced microglial phagocytosis. Biol Pharm Bull 2008;31: 1711–5.PubMedGoogle Scholar
  136. 136.
    Roy A, Jana A, Yatish K, et al. Reactive oxygen species upregulate CD11b in microglia via nitric oxide: Implications for neurodegenerative diseases. Free Radic Biol Med 2008;45: 686–99.PubMedGoogle Scholar
  137. 137.
    Wu DC, Teismann P, Tieu K, et al. NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson’s disease. Proc Natl Acad Sci U S A 2003;100: 6145–50.PubMedGoogle Scholar
  138. 138.
    Block ML. NADPH oxidase as a therapeutic target in Alzheimer’s disease. BMC Neurosci 2008;9(suppl 2): S8.PubMedGoogle Scholar
  139. 139.
    Wu XF, Block ML, Zhang W, et al. The role of microglia in paraquat-induced dopaminergic neurotoxicity. Antioxid Redox Signal 2005;7: 654–61.PubMedGoogle Scholar
  140. 140.
    Gao HM, Liu B, Zhang W, Hong JS. Critical role of microglial NADPH oxidase-derived free radicals in the in vitro MPTP model of Parkinson’s disease. FASEB J 2003;17: 1954–1956.PubMedGoogle Scholar
  141. 141.
    Won SY, Choi SH, Jin BK. Prothrombin kringle-2-induced oxidative stress contributes to the death of cortical neurons in vivo and in vitro: role of microglial NADPH oxidase. J Neuroimmunol 2009;214: 83–92.PubMedGoogle Scholar
  142. 142.
    Qian L, Hu X, Zhang D, et al. beta2 Adrenergic receptor activation induces microglial NADPH oxidase activation and dopaminergic neurotoxicity through an ERK-dependent/protein kinase A-independent pathway. Glia 2009;57: 1600–9.PubMedGoogle Scholar
  143. 143.
    Rodriguez-Pallares J, Rey P, Parga JA, Munoz A, Guerra MJ, Labandeira-Garcia JL. Brain angiotensin enhances dopaminergic cell death via microglial activation and NADPH-derived ROS. Neurobiol Dis 2008;31: 58–73.PubMedGoogle Scholar
  144. 144.
    Hur J, Lee P, Kim MJ, Kim Y, Cho YW. Ischemia-activated microglia induces neuronal injury via activation of gp91phox NADPH oxidase. Biochem Biophys Res Commun;391:1526–30.Google Scholar
  145. 145.
    Green SP, Cairns B, Rae J, et al. Induction of gp91-phox, a component of the phagocyte NADPH oxidase, in microglial cells during central nervous system inflammation. J Cereb Blood Flow Metab 2001;21: 374–84.PubMedGoogle Scholar
  146. 146.
    Wang T, Liu B, Qin L, Wilson B, Hong JS. Protective effect of the SOD/catalase mimetic MnTMPyP on inflammation-mediated dopaminergic neurodegeneration in mesencephalic neuronal-glial cultures. J Neuroimmunol 2004;147: 68–72.PubMedGoogle Scholar
  147. 147.
    Li Y, Trush MA. Diphenyleneiodonium, an NAD(P)H oxidase inhibitor, also potently inhibits mitochondrial reactive oxygen species production. Biochem Biophys Res Commun 1998;253: 295–9.PubMedGoogle Scholar
  148. 148.
    Block ML, Li G, Qin L, et al. Potent regulation of microglia-derived oxidative stress and dopaminergic neuron survival: substance P vs. dynorphin. Faseb J 2006;20: 251–8.PubMedGoogle Scholar
  149. 149.
    Konishi H, Tanaka M, Takemura Y, et al. Activation of protein kinase C by tyrosine phosphorylation in response to H2O2. Proc Natl Acad Sci U S A 1997;94: 11233–7.PubMedGoogle Scholar
  150. 150.
    Guyton KZ, Gorospe M, Kensler TW, Holbrook NJ. Mitogenactivated protein kinase (MAPK) activation by butylated hydroxytoluene hydroperoxide: implications for cellular survival and tumor promotion. Cancer Res 1996;56: 3480–5.PubMedGoogle Scholar
  151. 151.
    Schreck R, Rieber P, Baeuerle PA. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1. Embo J 1991;10: 2247–58.PubMedGoogle Scholar
  152. 152.
    Forman HJ, Torres M. Reactive oxygen species and cell signaling: respiratory burst in macrophage signaling. Am J Respir Crit Care Med 2002;166: S4–8.PubMedGoogle Scholar
  153. 153.
    Wang T, Qin L, Liu B, et al. Role of reactive oxygen species in LPS-induced production of prostaglandin E2 in microglia. J Neurochem 2004;88: 939–47.PubMedGoogle Scholar
  154. 154.
    Min KJ, Pyo HK, Yang MS, Ji KA, Jou I, Joe EH. Gangliosides activate microglia via protein kinase C and NADPH oxidase. Glia 2004;48: 197–206.PubMedGoogle Scholar
  155. 155.
    Pawate S, Shen Q, Fan F, Bhat NR. Redox regulation of glial inflammatory response to lipopolysaccharide and interferon-gamma. J Neurosci Res 2004;77: 540–51.PubMedGoogle Scholar
  156. 156.
    Qin L, Wu X, Block ML, et al. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 2007;55: 453–62.PubMedGoogle Scholar
  157. 157.
    Gao HK, Yin Z, Zhou N, Feng XY, Gao F, Wang HC. Glycogen synthase kinase 3 inhibition protects the heart from acute ischemia-reperfusion injury via inhibition of inflammation and apoptosis. J Cardiovasc Pharmacol 2008;52: 286–92.PubMedGoogle Scholar
  158. 158.
    Huh Y, Jung JW, Park C, et al. Microglial activation and tyrosine hydroxylase immunoreactivity in the substantia nigral region following transient focal ischemia in rats. Neurosci Lett 2003;349: 63–7.PubMedGoogle Scholar
  159. 159.
    McGeer PL, Schwab C, Parent A, Doudet D. Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration. Ann Neurol 2003;54: 599–604.PubMedGoogle Scholar
  160. 160.
    Przedborski S, Tieu K, Perier C, Vila M. MPTP as a mitochondrial neurotoxic model of Parkinson’s disease. J Bioenerg Biomembr 2004;36: 375–9.PubMedGoogle Scholar
  161. 161.
    Wu DC, Jackson-Lewis V, Vila M, et al. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 2002;22: 1763–71.PubMedGoogle Scholar
  162. 162.
    Liberatore GT, Jackson-Lewis V, Vukosavic S, et al. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat Med 1999;5: 1403–9.PubMedGoogle Scholar
  163. 163.
    Zhang W, Wang T, Qin L, et al. Neuroprotective effect of dextromethorphan in the MPTP Parkinson’s disease model: role of NADPH oxidase. Faseb J 2004;18: 589–91.PubMedGoogle Scholar
  164. 164.
    Feng ZH, Wang TG, Li DD, et al. Cyclooxygenase-2-deficient mice are resistant to 1-methyl-4-phenyl1, 2, 3, 6-tetrahydropyridine-induced damage of dopaminergic neurons in the substantia nigra. Neurosci Lett 2002;329: 354–8.PubMedGoogle Scholar
  165. 165.
    Teismann P, Vila M, Choi DK, et al. COX-2 and neurodegeneration in Parkinson’s disease. Ann N Y Acad Sci 2003;991: 272–7.PubMedGoogle Scholar
  166. 166.
    Levesque S, Wilson B, Gregoria V, et al. Reactive Microgliosis: Extracellular μ Calpain and Microglia-mediated Dopaminergic Neurotoxicity. Brain 2010;133: 808–821.PubMedGoogle Scholar
  167. 167.
    Kim YS, Choi DH, Block ML, et al. A pivotal role of matrix metalloproteinase-3 activity in dopaminergic neuronal degeneration via microglial activation. Faseb J 2007;21: 179–87.PubMedGoogle Scholar
  168. 168.
    Zecca L, Zucca FA, Wilms H, Sulzer D. Neuromelanin of the substantia nigra: a neuronal black hole with protective and toxic characteristics. Trends Neurosci 2003;26: 578–80.PubMedGoogle Scholar
  169. 169.
    Ling Z, Gayle DA, Ma SY, et al. In utero bacterial endotoxin exposure causes loss of tyrosine hydroxylase neurons in the postnatal rat midbrain. Mov Disord 2002;17: 116–24.PubMedGoogle Scholar
  170. 170.
    Ling Z, Zhu Y, Tong CW, Snyder JA, Lipton JW, Carvey PM. Progressive dopamine neuron loss following supra-nigral lipopolysaccharide (LPS) infusion into rats exposed to LPS prenatally. Exp Neurol 2006.Google Scholar
  171. 171.
    Carvey PM, Chang Q, Lipton JW, Ling Z. Prenatal exposure to the bacteriotoxin lipopolysaccharide leads to long-term losses of dopamine neurons in offspring: a potential, new model of Parkinson’s disease. Front Biosci 2003;8: s826–37.PubMedGoogle Scholar
  172. 172.
    Gayle DA, Ling Z, Tong C, Landers T, Lipton JW, Carvey PM. Lipopolysaccharide (LPS)-induced dopamine cell loss in culture: roles of tumor necrosis factor-alpha, interleukin-1beta, and nitric oxide. Brain Res Dev Brain Res 2002;133: 27–35.PubMedGoogle Scholar
  173. 173.
    Ling ZD, Chang Q, Lipton JW, Tong CW, Landers TM, Carvey PM. Combined toxicity of prenatal bacterial endotoxin exposure and postnatal 6-hydroxydopamine in the adult rat midbrain. Neuroscience 2004;124: 619–28.PubMedGoogle Scholar
  174. 174.
    Niehaus I. Lippopolysaccharides induce inflammation-mediated neurodeheneration in the substantia nigra and the cerebral cortex (A case report). AD/PD 6th International Conference, 2003:1–38.Google Scholar
  175. 175.
    Cunningham C, Campion S, Lunnon K, et al. Systemic inflammation induces acute behavioral and cognitive changes and accelerates neurodegenerative disease. Biol Psychiatry 2009;65: 304–12.PubMedGoogle Scholar
  176. 176.
    Lehnardt S, Massillon L, Follett P, et al. Activation of innate immunity in the CNS triggers neurodegeneration through a Toll-like receptor 4-dependent pathway. Proc Natl Acad Sci U S A 2003;100: 8514–9.PubMedGoogle Scholar
  177. 177.
    Henry CJ, Huang Y, Wynne AM, Godbout JP. Peripheral lipopolysaccharide (LPS) challenge promotes microglial hyperactivity in aged mice that is associated with exaggerated induction of both pro-inflammatory IL-1beta and anti-inflammatory IL-10 cytokines. Brain Behav Immun 2009;23: 309–17.PubMedGoogle Scholar
  178. 178.
    Godbout JP, Chen J, Abraham J, et al. Exaggerated neuroinflammation and sickness behavior in aged mice following activation of the peripheral innate immune system. Faseb J 2005;19: 1329–31.PubMedGoogle Scholar
  179. 179.
    Gao HM, Liu B, Zhang W, Hong JS. Synergistic dopaminergic neurotoxicity of MPTP and inflammogen lipopolysaccharide: relevance to the etiology of Parkinson’s disease. Faseb J 2003;17: 1957–9.PubMedGoogle Scholar
  180. 180.
    Carvey PM, Punati A, Newman MB. Progressive dopamine neuron loss in Parkinson’s disease: the multiple hit hypothesis. Cell Transplant 2006;15: 239–50.PubMedGoogle Scholar

Copyright information

© Springer 2010

Authors and Affiliations

  1. 1.Department of Anatomy and NeurobiologyVirginia Commonwealth University Medical CampusRichmond

Personalised recommendations